Driven by a number of high-profile buys in 2013, pharma saw a return to investment through acquisition after a 2012 dip.
Covidien is buying ingestible-camera company Given Imaging.
Already the world's third-largest generics maker, Actavis stands to gain if it can seal the deal
Having finally accepted that external R&D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they're not betting the farm on them, thanks to pre-nup-like earnout deals.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.